An integrated science-based approach to drug development

Current Opinion in Immunology

Volumn 20, Issue 4, 2008, Pages 426-430

  Parren, Paul WHI ^a   van de Winkel, Jan GJ ^a,b  

^a GENMAB   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ATLIZUMAB; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; NIMOTUZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; REDITUX; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ASTHMA; AUTOIMMUNE DISEASE; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLIOMA; GRAFT REJECTION; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATORY DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN ENGINEERING; RETINA MACULA DEGENERATION; RHEUMATOID ARTHRITIS; SOLID TUMOR; VIRAL RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; DRUG DESIGN; HUMANS; NEOPLASMS; THERAPEUTICS;

EID: 48549088457     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.06.006     Document Type: Editorial

References (13)

1. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol 6 (2006) 343-357
2. Desjarlais J.R., Lazar G.A., Zhukovsky E.A., and Chu S.Y. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12 (2007) 898-910
3. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker W, Dechant M, Beyer T, Repp R, Van Berkel PHC, Vink T, Van de Winkel JGJ, et al.: Antibody fucosylation differentially impacts cytotoxicity mediated by NK- and PMN-effector cells. Blood 2008, doi:10.1182/blood-2008-03-144600.
4. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., and Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008) 373-376
5. Matsumiya S., Yamaguchi Y., Saito J., Nagano M., Sasakawa H., Otaki S., Satoh M., Shitara K., and Kato K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 368 (2007) 767-779
6. Salfeld J.G. Isotype selection in antibody engineering. Nat Biotechnol 25 (2007) 1369-1372
7. Wypych J., Li M., Guo A., Zhang Z., Martinez T., Allen M.J., Fodor S., Kelner D.N., Flynn G.C., Liu Y.D., et al. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283 (2008) 16194-16205
8. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 (2007) 1554-1557
9. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouche O., Landi B., Louvet C., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 (2008) 374-379
10. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 (2008) 1789-1796
11. van Oers M.H., Klasa R., Marcus R.E., Wolf M., Kimby E., Gascoyne R.D., Jack A., Van't Veer M., Vranovsky A., Holte H., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108 (2006) 3295-3301
12. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., Goldhirsch A., Untch M., Mariani G., Baselga J., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
13. Dechant M., Weisner W., Berger S., Peipp M., Beyer T., Schneider-Merck T., Lammerts van Bueren J.J., Bleeker W.K., Parren P.W.H.I., van de Winkel J.G.J., et al. Complement-dependent tumor cell lysis triggered by combinations of EGF-R antibodies. Cancer Research 68 (2008) 4998-5003